The Jute Journal

Dundee’s PhaSER awarded $2.7m by Gates Foundation to make drugs using mice with humanised metabolism

A biomedical company linked to the University is accelerating drug development using mice with human metabolisms as it receives a grant from the Bill Gates Foundation.

Dundee Life Sciences Building

PhaSER Biomedical, the Dundee-based company uniquely developing lab mouse models with human-relevant metabolism in collaboration with the University of Dundee (UoD), has received a $2.7 million (£2 million) two-year grant from the Gates Foundation.

This builds on the $2.3 million awarded to PhaSER by the foundation in 2024. In return for the investment, PhaSER’s ‘8HUM’ mouse models and scientific expertise are made available to Gates grantees worldwide as part of the Global Health Discovery Collaboratory.

8HUM is important for exploring how compounds could be metabolised and eliminated from a human body, without complications from mouse-specific metabolic issues, by using modelling reactions in ‘humanised’ mice.

The UoD’s Professor Roland Wolf, who founded PhaSER Biomedical, said,

A man with glasses and a blue sweater
Prof. Roland Wolf, the founder of PhaSER. Image: University of Dundee

We are really excited about the continuation of this Collaboratory programme. Over the last two years we have seen how the humanised models provide human-relevant data that can rescue promising compounds, de-risk candidates and save valuable drug development time for the treatment diseases that affect millions of people. The renewal lets us build on our significant progress.

Aside from drug metabolism, 8HUM research is also applicable in pharmacokinetics, bioanalysis, computational modelling, and translational study design.

8HUM is also informing PhaSER’s ambitions to make an AI-driven drug-drug interaction analyser called HERALD.

Bringing together researchers from UoD and the UK Medicines and Healthcare products Regulatory Agency, PhaSER hopes to deepen interdisciplinary and international collaboration in drug discovery, and to tackle the major public health problem of patients experiencing adverse drug reactions when taking multiple medicines (polypharmacy).

Spotted a mistake? Email thejutejournal@dusamedia.com and we’ll look at it. Read our corrections policy.

More from this section

Latest

The weekly newsletter

Every Friday, the week’s stories in one email.